Crossover-Use of Human Antibiotics in Livestock in Agricultural Communities: A Qualitative Cross-Country Comparison between Uganda, Tanzania and India.
India
One Health
Tanzania
Uganda
antibiotic resistance
antibiotic stewardship
antibiotic use
crossover-use
qualitative
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
30 Sep 2022
30 Sep 2022
Historique:
received:
28
07
2022
revised:
02
09
2022
accepted:
28
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Antibiotic use in animal agriculture contributes significantly to antibiotic use globally and is a key driver of the rising threat of antibiotic resistance. It is becoming increasingly important to better understand antibiotic use in livestock in low-and-middle income countries where antibiotic use is predicted to increase considerably as a consequence of the growing demand for animal-derived products. Antibiotic crossover-use refers to the practice of using antibiotic formulations licensed for humans in animals and vice versa. This practice has the potential to cause adverse drug reactions and contribute to the development and spread of antibiotic resistance between humans and animals. We performed secondary data analysis of in-depth interview and focus-group discussion transcripts from independent studies investigating antibiotic use in agricultural communities in Uganda, Tanzania and India to understand the practice of antibiotic crossover-use by medicine-providers and livestock-keepers in these settings. Thematic analysis was conducted to explore driving factors of reported antibiotic crossover-use in the three countries. Similarities were found between countries regarding both the accounts of antibiotic crossover-use and its drivers. In all three countries, chickens and goats were treated with human antibiotics, and among the total range of human antibiotics reported, amoxicillin, tetracycline and penicillin were stated as used in animals in all three countries. The key themes identified to be driving crossover-use were: (1) medicine-providers' and livestock-keepers' perceptions of the effectiveness and safety of antibiotics, (2) livestock-keepers' sources of information, (3) differences in availability of human and veterinary services and antibiotics, (4) economic incentives and pressures. Antibiotic crossover-use occurs in low-intensity production agricultural settings in geographically distinct low-and-middle income countries, influenced by a similar set of interconnected contextual drivers. Improving accessibility and affordability of veterinary medicines to both livestock-keepers and medicine-providers is required alongside interventions to address understanding of the differences between human and animal antibiotics, and potential dangers of antibiotic crossover-use in order to reduce the practice. A One Health approach to studying antibiotic use is necessary to understand the implications of antibiotic accessibility and use in one sector upon antibiotic use in other sectors.
Identifiants
pubmed: 36290000
pii: antibiotics11101342
doi: 10.3390/antibiotics11101342
pmc: PMC9598773
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical Research Council
ID : MR/R00370X/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S013598/1
Pays : United Kingdom
Références
J Antibiot (Tokyo). 2021 Jun;74(6):417-420
pubmed: 33742170
BMC Vet Res. 2017 Jul 04;13(1):211
pubmed: 28676125
Front Vet Sci. 2021 Sep 08;8:611076
pubmed: 34568469
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Health Policy Plan. 2014 Jul;29 Suppl 1:i20-9
pubmed: 25012795
Soc Sci Med. 2021 Apr;275:113813
pubmed: 33721743
BMJ Open. 2016 Mar 15;6(3):e010632
pubmed: 26980439
Hum Resour Health. 2012 Feb 22;10:3
pubmed: 22357353
Antibiotics (Basel). 2021 Nov 23;10(12):
pubmed: 34943645
Vet Ital. 2012 Jan-Mar;48(1):87-93
pubmed: 22485005
Nat Commun. 2018 Apr 23;9(1):1599
pubmed: 29686259
PLoS One. 2018 Nov 21;13(11):e0207465
pubmed: 30462700
Int J Food Microbiol. 2006 Dec 1;112(3):280-7
pubmed: 16815582
J Pharm Policy Pract. 2020 Jun 03;13:20
pubmed: 32514362
J Pharm Policy Pract. 2021 Aug 20;14(1):69
pubmed: 34416911
BMC Health Serv Res. 2018 Jul 9;18(1):532
pubmed: 29986729
Lancet Planet Health. 2018 Nov;2(11):e489-e497
pubmed: 30396440
Med Anthropol. 2019 Apr;38(3):295-310
pubmed: 30526055
J Multidiscip Healthc. 2013 Aug 20;6:303-10
pubmed: 23990728
Lancet Infect Dis. 2021 Jan;21(1):107-115
pubmed: 32717205
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
One Health. 2020 Sep 02;10:100165
pubmed: 33117878
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
BMC Health Serv Res. 2019 Jul 31;19(1):536
pubmed: 31366363
Microbiologyopen. 2020 Sep;9(9):e1035
pubmed: 32710495
BMC Public Health. 2018 Aug 3;18(1):969
pubmed: 30075714
Antibiotics (Basel). 2021 Aug 23;10(8):
pubmed: 34439074
BMJ. 2017 Sep 5;358:j2687
pubmed: 28874365
BMC Public Health. 2017 Apr 19;17(1):333
pubmed: 28420365
Lancet. 2016 Jan 9;387(10014):168-75
pubmed: 26603918
PLoS One. 2016 Nov 8;11(11):e0164332
pubmed: 27824876
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Front Vet Sci. 2020 Feb 26;7:55
pubmed: 32175334
PLoS Med. 2016 Mar 02;13(3):e1001974
pubmed: 26934098
BMC Health Serv Res. 2017 Jun 19;17(1):416
pubmed: 28629475
Proc Natl Acad Sci U S A. 2015 May 5;112(18):5649-54
pubmed: 25792457
BMJ Glob Health. 2019 Sep 20;4(5):e001787
pubmed: 31637030
Lancet Glob Health. 2021 May;9(5):e610-e619
pubmed: 33713630
Antibiotics (Basel). 2020 Jan 28;9(2):
pubmed: 32013023
Lancet Planet Health. 2017 Apr;1(1):e33-e42
pubmed: 28670647
Antimicrob Resist Infect Control. 2016 Nov 11;5:42
pubmed: 27857835
PLoS One. 2020 Jan 24;15(1):e0220274
pubmed: 31978098
Antimicrob Resist Infect Control. 2015 Jul 21;4:30
pubmed: 26199723
Glob Health Action. 2017;10(1):1272223
pubmed: 28222653